Hypertension
An Introduction to Hypertension
Hypertension is one of the most significant risk factors for morbidity and mortality worldwide and is responsible for the deaths of approximately 9million people each year. Despite the availability of effective treatments, many people remain with high blood pressure that is not under optimal control. Advancing technologies are likely to play an important role in improving screening, detection and control of hypertension over the next few years.
Browse the content below where leading experts discuss the latest data in video interviews and short articles from our conference hub, and browse the selection of peer-reviewed articles from our journal portfolio.
Our supporting partners do not constitute an endorsement of the content on this page.
Hypertension is the leading modifiable risk factor for global cardiovascular disease, responsible for an estimated 10.8 million deaths and more than 200 million disability-adjusted life years annually.1Â Despite the availability of effective pharmacological and lifestyle interventions, prevalence continues to rise, particularly in ...
touchCARDIO Future Leaders 2026 Following the successful introduction last year of our touchCARDIO Future Leaders, we are delighted to announce that nominations are now open for the 2026 edition. This initiative celebrates the next generation of pioneers in cardiology, those whose passion, ...
From ACC26, Dr Matt Budoff shared his highlights, including the new cholesterol guidelines and imaging advances position coronary artery calcium scoring at the heart of personalized cardiovascular risk assessment and prevention.
At EHRA 2026, new research presented by Professor Elaine Chew explores how music-based digital tools can enhance arrhythmia detection and enable personalized, AI-driven approaches to cardiovascular diagnosis and therapy.
At ACC26, Dr Mardi Gomberg-Maitland presented results from the CADENCE trial, showing how sotatercept significantly improves pulmonary hemodynamics in HFpEF-associated pulmonary hypertension, offering hope for the first targeted therapy in this high-risk population.
Hypertension affects over 1.4 billion adults worldwide and remains the leading modifiable risk factor for global cardiovascular (CV) morbidity and mortality. It is responsible for an estimated 10.8 million deaths annually and contributes significantly to the global burden of ischaemic heart disease, ...
Hypertension has been associated with increased cardiovascular morbidity and mortality, as well as with overall elevated all-cause mortality.1 Prevalence increases with age, affecting 28.5% of US individuals aged 20–44 years, 58.6% of those aged 45–64 years and 76.5% of those aged 65 years and older.2 In ...
We are delighted to welcome Dr Sushant Saluja, NIHR Clinical Lecturer in Cardiology at the University of Manchester, to our Editorial Board. Dr Saluja brings a distinguished record in interventional cardiology, population genetics and precision medicine, with research published in leading journals including Nature Genetics, Nature Communications, European Heart Journal and the Journal of Hypertension.
The 2025 American Heart Association (AHA) Scientific Sessions (7–10 November; New Orleans, LA, USA) offered a comprehensive overview of the evolving landscape of cardiovascular medicine. This year’s research showcased pivotal trials spanning indications, including hypercholesterolemia, hypertrophic cardiomyopathy, amyloidosis, severe hypertriglyceridaemia, hypertension, ...
A phase 3 trial presented at the ESC Congress 2025 reported that the selective aldosterone synthase inhibitor baxdrostat achieved significant reductions in blood pressure in patients with uncontrolled or resistant hypertension.1
July 2025 marked continued progress in cardiovascular innovation, with notable regulatory decisions and clinical trial milestones. Approvals, designations, and data readouts during the month highlight the field’s ongoing shift toward targeted therapies, gene-based interventions, and outcome-driven evidence. These developments reflect growing momentum in addressing complex and underserved cardiovascular conditions.
June was a dynamic month in cardiovascular medicine, marked by notable regulatory approvals and clinical trial progress across several therapeutic areas. Advances in hypertension management, lipid lowering and cardiometabolic care continue to shape the treatment landscape, while evolving data in pulmonary arterial hypertension underscore the importance of ongoing innovation. This month’s roundup highlights the latest developments poised to impact clinical practice and patient outcomes.
The touchCARDIO journal Heart International has once again seen an increase in its Journal Impact Factor (JIF), rising from 1.9 in 2024 to 2.3 in 2025.
Physician burnout is at a critical point. In this episode, Nicky speaks with Dr Alfred Atanda about why so many physicians are burning out and what can be done to change the trend. From personal experience to system-wide solutions, Dr Atanda shares valuable insights on improving physician well-being and building a more effective healthcare culture.
What if your medical degree could launch more than a clinical career? In this candid and compelling read, Dr Jon Edelson shares his lessons for early-career clinicians ready to think beyond the bedside and explore the business of medicine.
touchCARDIO is delighted to announce that Heart International has received an impressive new Impact Factor of 1.9 in the 2024 Journal Citation Reports (JCR). This achievement marks a notable increase from last year’s Impact Factor of 0.2 and highlights the journal’s growing influence in the cardiology field.
A recent study published in The American Journal of Medicine reported the benefits of high fruit and vegetable diets and oral sodium bicarbonate (NaHCO3) for managing hypertension-related chronic kidney disease (CKD) and cardiovascular disease
Log into your Touch Account
Keep track of your clinical interests and newsletter subscriptions.
Sign up with an Email
Or use a .
Register now for FREE access
Already registered? Login below.
